Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | SLC10A2 | Q12908 | 5/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.31 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.31 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22286373 | 0.93 | NR1H4 (0.38) | NR1H4SLC10A2THRATHRB | |
| SCHEMBL22286371 | 0.93 | NR1H4 (0.38) | NR1H4SLC10A2THRATHRB | |
| SCHEMBL22286518 | 0.93 | NR1H4 (0.38) | NR1H4SLC10A2THRATHRB | |
| SCHEMBL22286647 | 0.92 | NR1H4 (0.45) | NR1H4SLC10A2CYP2C19 | |
| SCHEMBL22286670 | 0.92 | NR1H4 (0.45) | NR1H4SLC10A2CYP2C19 | |
| SCHEMBL22286553 | 0.92 | NR1H4 (0.45) | NR1H4SLC10A2CYP2C19 | |
| SCHEMBL22286630 | 0.91 | NR1H4 (0.44) | NR1H4SLC10A2CYP2C19THRATHRB | |
| SCHEMBL22286437 | 0.89 | NR1H4 (0.43) | NR1H4SLC10A2CYP2C19THRATHRB | |
| SCHEMBL22286541 | 0.87 | NR1H4 (0.46) | NR1H4 | |
| SCHEMBL22286513 | 0.87 | NR1H4 (0.46) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | claimed |
| EP-3921027-B1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-07-19 | — | — | EP | claimed |
| EP-3921027-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2021-12-15 | — | — | EP | claimed |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | Aibireo AB (SE) | 2021-04-13 | — | — | US | claimed |
| WO-2020161216-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | claimed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | claimed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| EP-3921027-B1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3921027-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2021-12-15 | — | — | EP | disclosed |
| US-20210147372-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-05-20 | — | — | US | disclosed |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | Aibireo AB (SE) | 2021-04-13 | — | — | US | disclosed |
| WO-2020161216-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885SLC10A2 2/4885CYP2C19 347/4885 |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885SLC10A2 2/4885CYP2C19 347/4885 |
| US-20210147372-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885SLC10A2 2/4885CYP2C19 347/4885 |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885SLC10A2 2/4885CYP2C19 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.